Merck is expanding its alliance with Intercell to find a new therapy for Group A Streptococcus. Their new pact includes a $9.5 million up front payment and up to $76 million in milestone payments. The agreement centers on antigens discovered using Intercell's technology platform. Merck gains development options on antibodies that can be directed against the antigens. Strep is a big driver of doctor's visits and a leading reason why doctor's prescribe antibiotics for children.
- read the AFX report on the pact